The groupings / Health Care / Biotechnology
Biotechnology
69 companies across the library’s three pools, one row each. The columns are the line items this kind of business is read on; each header names its basis, and the margins and returns are medians over each company’s readable record — the through-cycle level, never one year’s print. Rows open largest first by latest-year revenue, and every column sorts both ways — the re-ordering is the reader’s own act, and a sorted view keeps its order in the address bar. The company stays in view as the columns scroll. A dash is a figure that could not be read; n/a is one that does not apply to that member; both sit at the back of a sorted column.
From the latest filings · data as of August 17, 2026.
As a group: median revenue $102M; median gross margin 67.4%; median operating margin -106.6%; median owner earnings ($71M); median return on invested capital -42.3%; 51 of 69 hold net cash. Medians of this table’s own columns, over the members each applies to · data as of August 17, 2026.
| latest fiscal year, USD | median over the record | median over the record | op. cash − maintenance capex · latest FY, USD | after tax · median over the record | debt − cash & ST investments · latest FY, USD | ||||
|---|---|---|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | Biotechnology | $36.8B | 75.7% | 36.1% | $8.1B | 17.7% | $45.5B | |
| GILD | Gilead Sciences Inc. | Biotechnology | $29.4B | 79.0% | 31.0% | $9.5B | 15.2% | $25.9B | |
| BIIB | Biogen Inc. | Biotechnology | $9.9B | 83.6% | 34.6% | $2.1B | 18.3% | $3.3B | |
| IDXX | IDEXX Laboratories Inc. | Biotechnology | $4.3B | 58.4% | 26.2% | $1.1B | 56.8% | $519M | |
| BNTX | BioNTech SE American Depositary Share | Biotechnology | $3.3B | 84.3% | -42.2% | $465M | -10.2% | +$17.0B cash | |
| NBIX | Neurocrine | Biotechnology | $2.9B | 98.5% | 13.3% | $757M | 10.2% | +$713M cash | |
| QDEL | QuidelOrtho | Biotechnology | $2.7B | — | 15.2% | ($83M) | -21.4% · 2y | $2.7B | |
| EXEL | Exelixis Inc. | Biotechnology | $2.3B | 96.4% | 23.9% | $876M | 11.1% | +$870M cash | |
| QGEN | Qiagen N.V. | Biotechnology | $2.1B | 64.5% | 19.2% | $453M | 6.6% | $556M | |
| MRNA | Moderna Inc. | Biotechnology | $1.9B | 55.1% · 4y | -121.9% | ($2.1B) | -34.7% | +$2.0B cash | |
| LNTH | Lantheus Holdings | Biotechnology | $1.5B | 50.6% | 17.2% | $354M | 23.7% | $210M | |
| HALO | Halozyme | Biotechnology | $1.4B | 82.6% | 37.1% | $645M | 17.1% | $2.0B | |
| TECH | Bio-Techne | Biotechnology | $1.2B | 66.9% | 21.4% | $257M | 9.4% | $184M | |
| NVAX | Novavax Inc. | Biotechnology | $1.1B | 65.1% · 3y | -87.6% | ($250M) | -127.7% | +$491M cash | |
| BCRX | BioCryst Pharmaceuticals Inc. | Biotechnology | $875M | 95.5% | -113.1% | $346M | -141.8% · 3y | +$275M cash | |
| NEOG | Neogen | Biotechnology | $870M | 46.9% | 13.5% | $32M | 8.1% | $608M | |
| MYGN | Myriad Genetics Inc. | Biotechnology | $825M | 70.1% | -17.7% | — | -14.3% | +$30M cash | |
| RGEN | Repligen Corporation | Biotechnology | $738M | 55.2% | 13.4% | $94M | 4.3% | +$225M cash | |
| ALVO | Alvotech | Biotechnology | $586M | 41.3% | -297.3% | ($88M) | -64.9% | $1.1B | |
| ADMA | ADMA Biologics Inc | Biotechnology | $510M | -13.3% | -106.6% | $42M | -38.8% | $12M | |
| TARS | Tarsus Pharmaceuticals Inc. | Biotechnology | $451M | — | -65.9% | ($13M) | -41.2% | +$345M cash | |
| IMCR | Immunocore Holdings plc | Biotechnology | $400M | 98.7% · 1y | -23.3% | ($14M) | — | +$864M cash | |
| KRYS | Krystal Biotech | Biotechnology | $389M | — | 22.6% | $189M | -21.4% | +$492M cash | |
| TWST | Twist Bioscience Corporation | Biotechnology | $377M | 37.8% | -115.4% | ($76M) | -50.9% | +$231M cash | |
| ADPT | Adaptive Biotechnologies Corporation | Biotechnology | $277M | 68.1% | -108.0% | ($49M) | -31.7% | $61M | |
| VCEL | Vericel Corporation | Biotechnology | $276M | 67.9% | -4.7% | $40M | -3.7% | +$137M cash | |
| IOVA | Iovance Biotherapeutics Inc. | Biotechnology | $264M | 34.3% · 3y | -197.0% · 2y | ($336M) | -59.5% | +$296M cash | |
| VALN | Valneva SE | Biotechnology | $203M | 41.9% | -31.4% | ($67M) | -42.3% | $77M | |
| RGNX | REGENXBIO Inc. | Biotechnology | $170M | 68.2% | -233.2% | ($126M) | -46.7% | +$230M cash | |
| DNA | Ginkgo Bioworks Holdings Inc. | Biotechnology | $170M | — | -246.5% | ($179M) | -350.6% | +$423M cash | |
| BEAM | Beam Therapeutics Inc. | Biotechnology | $140M | — | -555.6% | ($360M) | -63.1% | +$1.2B cash | |
| GLUE | Monte Rosa Therapeutics Inc. | Biotechnology | $124M | — | -75.5% · 2y | ($27M) | -131.4% · 2y | +$130M cash | |
| IBRX | ImmunityBio Inc. | Biotechnology | $113M | — | -226.0% · 1y | ($309M) | -50.2% · 4y | $82M | |
| IPSC | Century Therapeutics Inc. | Biotechnology | $109M | — | -15.8% · 1y | ($105M) | -65.2% | +$107M cash | |
| STRO | Sutro Biopharma Inc. | Biotechnology | $102M | — | -142.2% | — | -48.7% | +$137M cash | |
| FDMT | 4D Molecular Therapeutics Inc. | Biotechnology | $85M | — | -416.3% | ($110M) | -41.1% | +$403M cash | |
| MGTX | MeiraGTx Holdings plc | Biotechnology | $81M | — | -420.2% | ($50M) | -134.1% | +$16M cash | |
| AUTL | Autolus Therapeutics PLC | Biotechnology | $75M | -20.2% · 2y | -358.9% · 1y | ($292M) | -192.1% · 2y | +$104M cash | |
| ABCL | AbCellera Biologics Inc. | Biotechnology | $75M | — | 4.6% | ($174M) | -18.4% | +$129M cash | |
| RXRX | Recursion Pharmaceuticals Inc. | Biotechnology | $75M | 4.7% | -799.7% | ($378M) | -105.6% | +$734M cash | |
| CLLS | Cellectis S.A. | Biotechnology | $73M | 25.0% · 3y | -341.0% | ($42M) | -205.6% | +$73M cash | |
| CGEN | Compugen Ltd. | Biotechnology | $73M | 88.0% | -92.0% | $31M | -37.0% | +$100M cash | |
| VIR | Vir Biotechnology Inc. | Biotechnology | $69M | 95.4% · 4y | -544.0% | ($397M) | -44.7% | +$461M cash | |
| NTLA | Intellia Therapeutics Inc. | Biotechnology | $68M | — | -282.5% | ($396M) | -44.5% | +$450M cash | |
| MESO | Mesoblast Limited | Biotechnology | $65M | 70.2% · 1y | -488.4% | ($61M) | -11.1% | +$3M cash | |
| PLX | Protalix BioTherapeutics Inc. (DE) | Biotechnology | $53M | 58.9% | -23.5% | ($14M) | -0.6% · 4y | $14M | |
| FENC | Fennec Pharmaceuticals Inc. | Biotechnology | $45M | 94.2% · 2y | -14.1% · 3y | — | -167.0% · 1y | +$17M cash | |
| KYMR | Kymera Therapeutics Inc. | Biotechnology | $39M | 0.0% | -277.5% | ($234M) | -25.7% | +$357M cash | |
| CCCC | C4 Therapeutics Inc. | Biotechnology | $36M | — | -336.1% | ($99M) | -50.0% | +$75M cash | |
| XFOR | X4 Pharmaceuticals Inc. | Biotechnology | $35M | 76.2% · 2y | -247.4% · 1y | ($86M) | -175.4% | +$142M cash | |
| RLAY | Relay Therapeutics Inc. | Biotechnology | $15M | — | -67.5% · 1y | ($236M) | -45.8% | +$84M cash | |
| IPHA | Innate Pharma S.A. ADS | Biotechnology | $10M | — | -90.8% | ($62M) | -1025.6% · 3y | +$40M cash | |
| ACOG | Alpha Cognition Inc. | Biotechnology | $10M | — | -221.7% · 1y | ($20M) | — | +$65M cash | |
| TSHA | Taysha Gene Therapies Inc. | Biotechnology | $10M | — | -468.8% · 1y | ($94M) | — | +$270M cash | |
| NNNN | Anbio Biotechnology | Biotechnology | $9M | 53.4% | 36.3% | — | 37.5% | +$12M cash | |
| EVAX | Evaxion A/S American Depositary Share | Biotechnology | $8M | — | -281.6% · 2y | ($7M) | -1319.6% | +$9M cash | |
| FATE | Fate Therapeutics Inc. | Biotechnology | $7M | — | -388.6% | ($112M) | -56.3% | +$189M cash | |
| ABEO | Abeona Therapeutics Inc. | Biotechnology | $6M | 73.7% · 1y | -814.2% · 1y | ($79M) | -80.1% | +$171M cash | |
| DBVT | DBV Technologies S.A. | Biotechnology | $6M | — | -486.0% · 1y | ($122M) | -1205.9% · 3y | +$193M cash | |
| PRME | Prime Medicine Inc. | Biotechnology | $5M | — | -17.9% · 1y | ($167M) | -176.8% | +$63M cash | |
| OCGN | Ocugen Inc. | Biotechnology | $4M | — | — | ($57M) | -783.8% · 2y | $10M | |
| CGON | CG Oncology Inc. | Biotechnology | $4M | — | — | ($132M) | -19.9% · 2y | +$739M cash | |
| CRSP | CRISPR Therapeutics AG | Biotechnology | $4M | — | -21.9% · 4y | ($346M) | -27.3% | +$1.9B cash | |
| CLDX | Celldex Therapeutics Inc. | Biotechnology | $2M | 95.7% | -854.1% · 1y | ($214M) | -38.3% | +$507M cash | |
| PLUR | Pluri Inc. | Biotechnology | $1M | 49.0% · 1y | -819.1% · 1y | ($19M) | -68.3% | $18M | |
| PROK | ProKidney Corp. | Biotechnology | $893K | — | — | ($127M) | — | +$109M cash | |
| ALLO | Allogene Therapeutics Inc. | Biotechnology | $0 | — | -157.9% · 1y | ($150M) | -43.8% | +$52M cash | |
| DNLI | Denali Therapeutics Inc. | Biotechnology | $0 | — | -186.8% | ($422M) | -32.7% | +$868M cash | |
| PALI | Palisade Bio Inc. | Biotechnology | $0 | — | — | — | -1528.8% · 4y | +$133M cash |
Every figure is recomputed from the company’s own SEC or EDINET filings, the same way as on its page; the columns name facts, weigh nothing, and form no rank. Foreign filers are stated in US dollars at the dated reference rate (as of 2026-08-20) so each money column sorts on one basis; their own pages keep the records as filed. A foreign filer whose conversion terms are missing shows its money as filed and sorts to the back of the column — never a guessed conversion. Ratios and margins are currency-free.